We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Next-Generation Multiomics Blood-Based Test for Pancreatic Cancer Could Become Powerful Tool for Early Diagnosis and Treatment

By LabMedica International staff writers
Posted on 07 Oct 2021
Print article
Illustration
Illustration

Freenome Holdings, Inc. (South San Francisco, CA, USA) has demonstrated the potential of extending its multiomics approach into other cancers, such as pancreatic cancer, with biomarkers already embedded in the existing platform.

Pancreatic cancer is one of the deadliest cancers, with an overall five-year survival rate of 11%. If detected at an early stage, the five-year survival rate increases to 42%. The only FDA-authorized test for pancreatic cancer is the carbohydrate antigen 19-9 (CA19-9), which is only cleared for monitoring response to therapy.

The retrospective study of 75 participants evaluated whether Freenome's multiomics approach of combining methylation and CA19-9 signals together (as a subset of existing analytes in the platform) detected pancreatic cancer in stages II, III and IV with higher sensitivity than either alone. Across all stages studied, Freenome's approach achieved a sensitivity of 93% at a nominal specificity of 96%. At an identical specificity, the sensitivity of methylation or CA19-9 alone was 74% and 87%, respectively. In stages II, III and IV, the multiomics approach achieved a sensitivity of 82%, 89%, and 100%, respectively.

The new study demonstrates that Freenome's platform can be used to detect pancreatic cancer in addition to colorectal cancer (CRC). Last year, Freenome presented data showing a sensitivity of 94% at a specificity of 94% for early-stage (I/II) CRC using their multiomics platform. Freenome's CRC test is currently undergoing analytical and clinical validation.

"We're demonstrating success in detecting CRC and advanced adenomas in blood. We're now expanding our platform to detect additional cancers," said Mike Nolan, chief executive officer, Freenome. "Our goal is to transform the way cancer of all types is managed by enabling early detection, and this data on pancreatic cancer is an important step in that direction."

"An accurate blood-based test like this could be a powerful tool for early diagnosis and treatment, impacting so many patients," said Randall Brand, M.D., professor of Medicine and Human Genetics at the University of Pittsburgh School of Medicine, and co-author of the study. "We are hoping to further validate the findings through additional studies, which are already underway."

Related Links:
Freenome Holdings, Inc. 

New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Silver Member
Static Concentrator
BJP 10
New
Silver Member
Rubella Infection ELISA
ReQuest RUBELLA IgM ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)

AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. However, training AI... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.